We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
ACP2 is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
45.0
Number of samples
141
Samples
Sample
Description
TPM
TCGA-14-1034-01A
0 years, female, stage:'--, dead, 485 days
73.7
TCGA-28-5204-01A
0 years, male, white, stage:'--, dead, 454 days
72.6
TCGA-28-5208-01A
0 years, male, white, stage:'--, dead, 544 days
65.9
TCGA-76-4927-01A
0 years, male, white, stage:'--, dead, 535 days
65.5
TCGA-06-0747-01A
0 years, male, white, stage:'--, dead, 82 days
64.5
TCGA-14-0787-01A
0 years, male, asian, stage:'--, dead, 68 days
64.4
TCGA-32-2616-01A
0 years, female, white, stage:'--, dead, 224 days
64.4
TCGA-28-1753-01A
0 years, male, white, stage:'--, alive, 37 days
64.1
TCGA-76-4929-01A
0 years, female, white, stage:'--, dead, 111 days
63.9
TCGA-06-0168-01A
0 years, female, white, stage:'--, dead, 598 days
63.9
TCGA-06-0211-01A
0 years, male, white, stage:'--, dead, 360 days
62.9
TCGA-12-0619-01A
0 years, male, white, stage:'--, dead, 1062 days
62.7
TCGA-06-0130-01A
0 years, male, white, stage:'--, dead, 394 days
62.5
TCGA-19-2619-01A
0 years, female, black or african american, stage:'--, alive, 294 days
62.4
TCGA-06-5410-01A
0 years, female, white, stage:'--, dead, 108 days
62.2
TCGA-14-0789-01A
0 years, male, white, stage:'--, dead, 342 days
61.1
TCGA-06-5859-01A
0 years, male, white, stage:'--, alive, 139 days
60.9
TCGA-06-5408-01A
0 years, female, white, stage:'--, dead, 357 days
60.7
TCGA-06-2562-01A
0 years, male, white, stage:'--, dead, 382 days
60.5
TCGA-06-2569-01A
0 years, female, black or african american, stage:'--, alive, 13 days
60.4
TCGA-06-0139-01A
0 years, male, white, stage:'--, dead, 362 days
59.2
TCGA-12-3653-01A
0 years, female, white, stage:'--, dead, 442 days
59.2
TCGA-06-0125-01A
0 years, female, white, stage:'--, dead, 1448 days
58.8
TCGA-06-0645-01A
0 years, female, white, stage:'--, dead, 175 days
58.8
TCGA-26-5135-01A
0 years, female, white, stage:'--, dead, 270 days
58.7
TCGA-27-2519-01A
0 years, male, white, stage:'--, dead, 550 days
58.6
TCGA-27-2523-01A
0 years, male, white, stage:'--, dead, 489 days
58.3
TCGA-06-0644-01A
0 years, male, black or african american, stage:'--, dead, 384 days
57.9
TCGA-32-1982-01A
0 years, female, white, stage:'--, dead, 142 days
57.9
TCGA-06-0878-01A
0 years, male, white, stage:'--, alive, 218 days
57.1
TCGA-76-4932-01A
0 years, female, white, stage:'--, dead, 1458 days
57.0
TCGA-06-0129-01A
0 years, male, asian, stage:'--, dead, 1024 days
56.6
TCGA-28-5209-01A
0 years, female, white, stage:'--, alive, 442 days
56.5
TCGA-19-2625-01A
0 years, female, white, stage:'--, dead, 124 days
56.1
TCGA-26-5139-01A
0 years, female, white, stage:'--, alive, 48 days
56.0
TCGA-28-5215-01A
0 years, female, white, stage:'--, dead, 335 days
55.6
TCGA-15-0742-01A
0 years, male, white, stage:'--, dead, 419 days
54.6
TCGA-06-2564-01A
0 years, male, white, stage:'--, alive, 181 days
54.5
TCGA-06-5412-01A
0 years, female, white, stage:'--, dead, 138 days
54.0
TCGA-32-1970-01A
0 years, male, white, stage:'--, dead, 468 days
53.7
TCGA-28-2513-01A
0 years, female, white, stage:'--, alive, 222 days
53.5
TCGA-06-0190-01A
0 years, male, white, stage:'--, dead, 317 days
53.5
TCGA-27-1832-01A
0 years, female, white, stage:'--, dead, 300 days
53.1
TCGA-06-5858-01A
0 years, female, white, stage:'--, alive, 187 days
52.9
TCGA-06-5414-01A
0 years, male, white, stage:'--, alive, 273 days
52.8
TCGA-12-5295-01A
0 years, female, white, stage:'--, dead, 454 days
52.7
TCGA-27-1837-01A
0 years, male, white, stage:'--, dead, 427 days
52.5
TCGA-41-4097-01A
0 years, female, white, stage:'--, dead, 6 days
52.5
TCGA-12-5299-01A
0 years, female, white, stage:'--, dead, 98 days
51.7
TCGA-19-2629-01A
0 years, male, white, stage:'--, dead, 737 days
51.6
TCGA-28-5207-01A
0 years, male, white, stage:'--, dead, 343 days
51.1
TCGA-32-2638-01A
0 years, male, white, stage:'--, dead, 766 days
50.9
TCGA-06-2561-01A
0 years, female, white, stage:'--, dead, 537 days
50.3
TCGA-06-0158-01A
0 years, male, white, stage:'--, dead, 329 days
49.5
TCGA-08-0386-01A
0 years, male, white, stage:'--, dead, 548 days
49.5
TCGA-06-0210-01A
0 years, female, white, stage:'--, dead, 225 days
49.3
TCGA-76-4931-01A
0 years, female, white, stage:'--, dead, 279 days
48.9
TCGA-06-2567-01A
0 years, male, white, stage:'--, dead, 133 days
48.2
TCGA-28-2514-01A
0 years, male, asian, stage:'--, alive, 160 days
48.1
TCGA-06-2557-01A
0 years, male, black or african american, stage:'--, dead, 33 days
48.0
TCGA-06-2563-01A
0 years, female, white, stage:'--, alive, 932 days
48.0
TCGA-06-0141-01A
0 years, male, white, stage:'--, dead, 313 days
47.5
TCGA-06-5418-01A
0 years, female, white, stage:'--, dead, 83 days
46.9
TCGA-06-0157-01A
0 years, female, white, stage:'--, dead, 97 days
46.7
TCGA-06-0750-01A
0 years, male, white, stage:'--, dead, 28 days
46.6
TCGA-41-2572-01A
0 years, male, white, stage:'--, dead, 406 days
45.9
TCGA-02-2483-01A
0 years, male, asian, stage:'--, alive, 466 days
45.7
TCGA-06-0646-01A
0 years, male, white, stage:'--, dead, 175 days
45.4
TCGA-19-2624-01A
0 years, male, white, stage:'--, dead, 5 days
44.9
TCGA-06-0187-01A
0 years, male, white, stage:'--, dead, 828 days
44.9
TCGA-12-0821-01A
0 years, male, white, stage:'--, dead, 323 days
44.9
TCGA-76-4925-01A
0 years, male, white, stage:'--, dead, 146 days
44.6
TCGA-15-1444-01A
0 years, male, white, stage:'--, dead, 1537 days
44.5
TCGA-19-4065-01A
0 years, male, white, stage:'--, alive, 214 days
44.2
TCGA-06-5413-01A
0 years, male, white, stage:'--, alive, 268 days
44.1
TCGA-26-5132-01A
0 years, male, white, stage:'--, alive, 286 days
43.8
TCGA-32-2632-01A
0 years, male, white, stage:'--, dead, 269 days
43.7
TCGA-02-2485-01A
0 years, male, black or african american, stage:'--, alive, 470 days
43.3
TCGA-32-1980-01A
0 years, male, white, stage:'--, dead, 36 days
43.3
TCGA-41-3915-01A
0 years, male, white, stage:'--, dead, 360 days
43.2
TCGA-27-2528-01A
0 years, male, white, stage:'--, dead, 480 days
43.0
TCGA-06-0174-01A
0 years, male, white, stage:'--, dead, 98 days
42.9
TCGA-27-1835-01A
0 years, female, white, stage:'--, dead, 648 days
42.8
TCGA-06-0745-01A
0 years, male, white, stage:'--, dead, 239 days
42.6
TCGA-06-0132-01A
0 years, male, white, stage:'--, dead, 771 days
42.5
TCGA-02-2486-01A
0 years, male, white, stage:'--, dead, 618 days
42.2
TCGA-28-2509-01A
0 years, female, white, stage:'--, alive, 145 days
41.7
TCGA-06-0882-01A
0 years, male, white, stage:'--, dead, 632 days
41.6
TCGA-06-0156-01A
0 years, male, white, stage:'--, dead, 178 days
41.5
TCGA-41-5651-01A
0 years, female, black or african american, stage:'--, dead, 460 days
41.0
TCGA-27-2524-01A
0 years, male, white, stage:'--, dead, 231 days
41.0
TCGA-02-0055-01A
0 years, female, white, stage:'--, dead, 76 days
40.9
TCGA-06-1804-01A
0 years, female, white, stage:'--, dead, 414 days
40.9
TCGA-16-0846-01A
0 years, male, white, stage:'--, dead, 119 days
40.4
TCGA-32-2634-01A
0 years, male, white, stage:'--, alive, 693 days
40.3
TCGA-32-2615-01A
0 years, male, white, stage:'--, dead, 485 days
40.3
TCGA-06-0686-01A
0 years, male, white, stage:'--, dead, 432 days
40.2
TCGA-06-2565-01A
0 years, male, asian, stage:'--, dead, 506 days
40.1
TCGA-28-5218-01A
0 years, male, white, stage:'--, dead, 157 days
40.0
TCGA-27-2526-01A
0 years, female, white, stage:'--, dead, 87 days
38.4
TCGA-06-0749-01A
0 years, male, black or african american, stage:'--, dead, 82 days
37.9
TCGA-06-5856-01A
0 years, male, white, stage:'--, dead, 114 days
37.8
TCGA-12-0618-01A
0 years, male, white, stage:'--, dead, 395 days
37.8
TCGA-12-3650-01A
0 years, male, white, stage:'--, dead, 333 days
37.6
TCGA-06-0184-01A
0 years, male, white, stage:'--, dead, 2126 days
37.1
TCGA-06-5411-01A
0 years, male, white, stage:'--, dead, 254 days
36.2
TCGA-06-2558-01A
0 years, female, white, stage:'--, dead, 380 days
35.8
TCGA-27-1834-01A
0 years, male, white, stage:'--, dead, 1233 days
35.4
TCGA-14-2554-01A
0 years, female, white, stage:'--, dead, 532 days
35.2
TCGA-06-0138-01A
0 years, male, white, stage:'--, dead, 737 days
35.1
TCGA-28-5220-01A
0 years, male, white, stage:'--, dead, 388 days
34.7
TCGA-06-5416-01A
0 years, female, white, stage:'--, alive, 204 days
34.6
TCGA-06-2559-01A
0 years, male, white, stage:'--, dead, 150 days
34.4
TCGA-32-4213-01A
0 years, female, white, stage:'--, alive, 604 days
34.3
TCGA-14-1825-01A
0 years, male, white, stage:'--, dead, 232 days
34.0
TCGA-12-3652-01A
0 years, male, white, stage:'--, dead, 1062 days
33.7
TCGA-27-1830-01A
0 years, male, white, stage:'--, dead, 154 days
33.3
TCGA-27-2521-01A
0 years, male, white, stage:'--, dead, 510 days
31.9
TCGA-19-2620-01A
0 years, male, white, stage:'--, dead, 148 days
31.3
TCGA-26-5133-01A
0 years, male, white, stage:'--, alive, 452 days
31.1
TCGA-06-0743-01A
0 years, male, white, stage:'--, dead, 803 days
30.4
TCGA-32-5222-01A
0 years, male, white, stage:'--, dead, 585 days
29.9
TCGA-26-1442-01A
0 years, male, white, stage:'--, alive, 953 days
29.5
TCGA-41-2571-01A
0 years, male, white, stage:'--, dead, 26 days
29.3
TCGA-19-1390-01A
0 years, female, white, stage:'--, dead, 772 days
28.9
TCGA-02-0047-01A
0 years, male, white, stage:'--, dead, 448 days
28.0
TCGA-06-2570-01A
0 years, female, white, stage:'--, alive, 958 days
28.0
TCGA-06-0744-01A
0 years, male, white, stage:'--, dead, 1426 days
27.6
TCGA-28-5216-01A
0 years, male, white, stage:'--, alive, 415 days
27.3
TCGA-12-0616-01A
0 years, female, white, stage:'--, dead, 448 days
25.5
TCGA-06-0238-01A
0 years, male, white, stage:'--, dead, 405 days
25.3
TCGA-19-5960-01A
0 years, male, white, stage:'--, dead, 455 days
25.1
TCGA-14-0817-01A
0 years, female, white, stage:'--, dead, 164 days
21.6
TCGA-14-1823-01A
0 years, female, white, stage:'--, dead, 543 days
21.0
TCGA-06-0178-01A
0 years, male, white, stage:'--, dead, 2681 days
19.9
TCGA-14-0871-01A
0 years, female, white, stage:'--, dead, 880 days
17.7
TCGA-06-5417-01A
0 years, female, white, stage:'--, alive, 155 days
16.8
TCGA-06-0219-01A
0 years, male, white, stage:'--, dead, 22 days
16.4
TCGA-27-1831-01A
0 years, male, white, stage:'--, dead, 505 days
16.3
TCGA-14-1829-01A
0 years, male, black or african american, stage:'--, alive, 218 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
ACP2 is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
8.4
Number of samples
58
Samples
Sample
Description
TPM
AK068
N, NA, stage:NA, alive, 360 days
15.7
AK088
N, NA, stage:NA, dead, 360 days
14.3
AK188
N, NA, stage:NA, alive, 420 days
13.3
AK076
N, NA, stage:NA, alive, 660 days
13.3
AK185
N, NA, stage:NA, alive, 330 days
13.0
AK005
N, NA, stage:NA, dead, 240 days
12.6
AK072
N, NA, stage:NA, dead, 150 days
12.4
AK035
N, NA, stage:NA, dead, 210 days
12.4
AK133
N, NA, stage:NA, dead, 360 days
11.9
AK236
N, NA, stage:NA, dead, 360 days
11.3
AK030
N, NA, stage:NA, dead, 120 days
11.0
AK153
N, NA, stage:NA, dead, 240 days
10.9
AK123
N, NA, stage:NA, dead, 180 days
10.7
AK227
N, NA, stage:NA, alive, 300 days
10.5
AK085
N, NA, stage:NA, alive, 660 days
10.4
AK195
N, NA, stage:NA, dead, 390 days
10.0
AK091
N, NA, stage:NA, dead, 210 days
9.9
AK099
N, NA, stage:NA, dead, 420 days
9.8
AK178
N, NA, stage:NA, dead, 240 days
9.8
AK079
N, NA, stage:NA, dead, 210 days
9.5
AK053
N, NA, stage:NA, dead, 300 days
9.5
AK226
N, NA, stage:NA, dead, 360 days
9.1
AK165
N, NA, stage:NA, alive, 360 days
8.9
AK100
N, NA, stage:NA, alive, 960 days
8.5
AK134
N, NA, stage:NA, dead, 360 days
8.5
AK041
N, NA, stage:NA, alive, 810 days
8.3
AK205
N, NA, stage:NA, dead, 120 days
8.2
AK139
N, NA, stage:NA, dead, 270 days
8.2
AK098
N, NA, stage:NA, dead, 660 days
8.1
AK216
N, NA, stage:NA, dead, 360 days
8.0
AK149
N, NA, stage:NA, dead, 420 days
8.0
AK167
N, NA, stage:NA, dead, 180 days
7.9
AK158
N, NA, stage:NA, dead, 360 days
7.8
AK089
N, NA, stage:NA, dead, 330 days
7.7
AK003
N, NA, stage:NA, dead, 600 days
7.7
AK071
N, NA, stage:NA, dead, 540 days
7.5
AK183
N, NA, stage:NA, alive, 360 days
7.5
AK074
N, NA, stage:NA, alive, 300 days
7.5
AK124
N, NA, stage:NA, alive, 1920 days
7.5
AK117
N, NA, stage:NA, dead, 210 days
7.4
AK043
N, NA, stage:NA, alive, 660 days
7.0
AK213
N, NA, stage:NA, alive, 2010 days
6.9
AK051
N, NA, stage:NA, dead, 360 days
6.6
AK081
N, NA, stage:NA, dead, 180 days
6.0
AK199
N, NA, stage:NA, alive, 1860 days
5.9
AK102
N, NA, stage:NA, alive, 1740 days
5.8
AK015
N, NA, stage:NA, alive, 720 days
5.8
AK049
N, NA, stage:NA, dead, 180 days
5.8
AK218
N, NA, stage:NA, dead, 180 days
5.5
AK173
N, NA, stage:NA, dead, 180 days
5.5
AK103
N, NA, stage:NA, alive, 1320 days
5.5
AK055
N, NA, stage:NA, dead, 240 days
5.4
AK231
N, NA, stage:NA, dead, 240 days
5.2
AK066
N, NA, stage:NA, alive, 960 days
4.1
AK142
N, NA, stage:NA, alive, 90 days
3.9
AK156
N, NA, stage:NA, dead, 330 days
3.9
AK006
N, NA, stage:NA, dead, 360 days
3.8
AK002
N, NA, stage:NA, dead, 570 days
3.2
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0218330004
Tumor
1.0
CPT0207090003
Tumor
0.9
CPT0216920008
Tumor
0.7
CPT0189650004
Tumor
0.6
CPT0186100003
Tumor
0.6
CPT0093550003
Tumor
0.5
CPT0217710008
Tumor
0.5
CPT0071100003
Tumor
0.5
CPT0064650003
Tumor
0.5
CPT0168480003
Tumor
0.5
CPT0224390004
Tumor
0.4
CPT0224540004
Tumor
0.4
CPT0127480003
Tumor
0.4
CPT0219080004
Tumor
0.4
CPT0206110003
Tumor
0.4
CPT0162020003
Tumor
0.4
CPT0168080003
Tumor
0.3
CPT0125220003
Tumor
0.3
CPT0167970003
Tumor
0.3
CPT0125570003
Tumor
0.3
CPT0089150003
Tumor
0.3
CPT0228220003
Tumor
0.3
CPT0206330003
Tumor
0.3
CPT0189750004
Tumor
0.3
CPT0125510003
Tumor
0.2
CPT0168590003
Tumor
0.2
CPT0205670004
Tumor
0.2
CPT0079790003
Tumor
0.2
CPT0221180003
Tumor
0.2
CPT0104220003
Tumor
0.2
CPT0087570003
Tumor
0.2
CPT0218690004
Tumor
0.2
CPT0225760003
Tumor
0.2
CPT0127420003
Tumor
0.2
CPT0182550003
Tumor
0.2
CPT0167530003
Tumor
0.2
CPT0087950003
Tumor
0.2
CPT0167640003
Tumor
0.2
CPT0064890003
Tumor
0.1
CPT0218830004
Tumor
0.1
CPT0161730003
Tumor
0.1
CPT0206450003
Tumor
0.1
CPT0175060003
Tumor
0.1
CPT0224600003
Tumor
0.1
CPT0168380003
Tumor
0.1
CPT0162100003
Tumor
0.1
CPT0093360003
Tumor
0.1
CPT0167860004
Tumor
0.1
CPT0190360004
Tumor
0.1
CPT0206000004
Tumor
0.1
CPT0168830003
Tumor
0.1
CPT0199770003
Tumor
0.1
CPT0217060003
Tumor
0.1
CPT0217000004
Tumor
0.1
CPT0093590003
Tumor
0.1
CPT0123530003
Tumor
0.1
CPT0196850003
Tumor
0.0
CPT0171580008
Tumor
0.0
CPT0218960004
Tumor
0.0
CPT0206230003
Tumor
0.0
CPT0209440003
Tumor
0.0
CPT0204370003
Normal
0.0
CPT0205780003
Tumor
0.0
CPT0092440003
Tumor
0.0
CPT0189570004
Tumor
0.0
CPT0204400003
Normal
0.0
CPT0206670004
Tumor
-0.1
CPT0168270003
Tumor
-0.1
CPT0207030003
Tumor
-0.1
CPT0217100003
Tumor
-0.1
CPT0189850004
Tumor
-0.1
CPT0205450004
Tumor
-0.1
CPT0205890003
Tumor
-0.1
CPT0218670003
Tumor
-0.1
CPT0189250003
Tumor
-0.1
CPT0217430008
Tumor
-0.1
CPT0204410003
Normal
-0.1
CPT0217880003
Tumor
-0.1
CPT0162140003
Tumor
-0.1
CPT0206880003
Tumor
-0.1
CPT0204420003
Normal
-0.1
CPT0204380003
Normal
-0.1
CPT0182500003
Tumor
-0.1
CPT0206780003
Tumor
-0.2
CPT0204360003
Normal
-0.2
CPT0167750004
Tumor
-0.2
CPT0182580003
Tumor
-0.2
CPT0168720003
Tumor
-0.2
CPT0189460003
Tumor
-0.2
CPT0087680003
Tumor
-0.2
CPT0087730003
Tumor
-0.2
CPT0225730003
Tumor
-0.2
CPT0093510003
Tumor
-0.2
CPT0204340003
Normal
-0.3
CPT0204350003
Normal
-0.3
CPT0206560003
Tumor
-0.3
CPT0104330003
Tumor
-0.3
CPT0224330003
Tumor
-0.3
CPT0205570003
Tumor
-0.3
CPT0093450003
Tumor
-0.3
CPT0078580003
Tumor
-0.4
CPT0190240004
Tumor
-0.4
CPT0217190003
Tumor
-0.4
CPT0208980003
Tumor
-0.4
CPT0002410011
Tumor
-0.4
CPT0218770003
Tumor
-0.5
CPT0201710003
Tumor
-0.5
CPT0204330003
Normal
-0.5
CPT0204390003
Normal
-0.5
CPT0218890004
Tumor
-0.6
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.